Design, synthesis and biological evaluation of novel N1,N8-bis(((4-((5-aryl-1,3,4-oxadiazol-2-yl)methoxy)phenyl)amino)oxy)-1-naphthamide derivatives

<p>A new series of 1,8-bis(4-((5-phenyl-1,3,4-oxadiazol-2-yl) methoxy)-substituted aryl) naphthalene-1,8-dicarboxamide derivatives (<b>6a–j)</b> were synthesized in the presence of POCl<sub>3</sub> and obtained good yields. All the synthesized novel compounds were characterized by IR, <sup>1</sup>H NMR, <sup>13</sup>C NMR, HRMS spectroscopic data and elemental analysis. All the synthesized compounds evaluated for their antibacterial and antifungal activities. The antibacterial activity screened against Gram-positive bacteria <i>Staphylococcus aureus</i> and Gram-negative bacteria <i>Escherichia coli</i> and used standard reference drug ciprofloxacin. The antifungal activity screened against two pathogenic fungal strains <i>Aspergillus niger</i> and <i>Candida albicans</i> used a reference standard drug Voriconazole. All these compounds (<b>6a–j)</b> demonstrate good antibacterial and antifungal activity. Among them, compounds <b>6h</b> and <b>6c</b> show highest antibacterial and antifungal activity.</p>